Clinical-stage biopharmaceutical company CymaBay Therapeutics, Inc. is dedicated to the development of therapies for treating liver and chronic diseases. Its lead product candidate, seladelpar (MBX-8025), is a selective agonist of peroxisome proliferator activated receptor delta designed to tackle autoimmune liver disease and primary biliary cholangitis (PBC). CymaBay also specializes in the creation of MBX-2982, a treatment for hypoglycemia in type 1 diabetics. With a license agreement secured with ABW Cyclops SPV LP to support the development of seladelpar for PBC treatment, as well as a worldwide license obtained from Janssen Pharmaceuticals, Inc. for the development and commercialization of compounds targeting an undisclosed metabolic disease, the company is making strides in its mission. Originally known as Metabolex, Inc., CymaBay Therapeutics, Inc. has been in operation since 1988 and is headquartered in Newark, California.
CymaBay Therapeutics's ticker is CBAY
The company's shares trade on the NASDAQ stock exchange
They are based in Newark, California
There are 11-50 employees working at CymaBay Therapeutics
It is cymabay.com/about_us.html
CymaBay Therapeutics is in the Healthcare sector
CymaBay Therapeutics is in the Biotechnology industry
The following five companies are CymaBay Therapeutics's industry peers: